If the data from our current and planned Phase I and II clinical trials of PARP inhibitors confirm that PBMCs can serve as a pharmacodynamic surrogate for drug effect on tumor, we may consider pre-enrollment screening in Phase III clinical trials for patients likely to benefit from ABT-888 treatment. This evidence concerns the gene PARP1 and neoplasm.